{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zeng H"],"funding":["the First Affiliated Hospital of Yangtze University","Heath and Family Planning Commission of Hubei Province","the Joint Fund project of Yangtze University"],"pagination":["221-230"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11216246"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(6)"],"pubmed_abstract":["<b>Objective:</b> This study intended to explore the relationship of PLK3 with prognosis in patients with colorectal cancer (CRC). <b>Methods:</b> PLK3 positivity was detected by immunohistochemistry in 160 patients with CRC receiving surgical resection. <b>Results:</b> The median tumor PLK3-positive rate was 26.5%. Tumor PLK3-positive rate was related to increased lymph node stage (p = 0.002) and tumor-node-metastasis stage (p < 0.001) of CRC. Tumor PLK3-positive rate ≥30% was related to shortened disease-free survival (p = 0.009) and overall survival (p = 0.003); tumor PLK3-positive rate ≥50% showed a stronger correlation with them (both p = 0.001), which was validated by multivariate Cox regression analyses (both p < 0.05). <b>Conclusion:</b> Tumor PLK3-positive rate ≥50% relates to inc"],"journal":["Biomarkers in medicine"],"pubmed_title":["PLK3 is linked with higher tumor stage and unfavorable prognosis in patients with colorectal cancer."],"pmcid":["PMC11216246"],"funding_grant_id":["WJ2019-22","WJ2018H203","2022DIF01"],"pubmed_authors":["Zhang W","Yang Y","Wang Q","Li S","He H","Xiang Y","Zeng H","Tu X"],"additional_accession":[]},"is_claimable":false,"name":"PLK3 is linked with higher tumor stage and unfavorable prognosis in patients with colorectal cancer.","description":"<b>Objective:</b> This study intended to explore the relationship of PLK3 with prognosis in patients with colorectal cancer (CRC). <b>Methods:</b> PLK3 positivity was detected by immunohistochemistry in 160 patients with CRC receiving surgical resection. <b>Results:</b> The median tumor PLK3-positive rate was 26.5%. Tumor PLK3-positive rate was related to increased lymph node stage (p = 0.002) and tumor-node-metastasis stage (p < 0.001) of CRC. Tumor PLK3-positive rate ≥30% was related to shortened disease-free survival (p = 0.009) and overall survival (p = 0.003); tumor PLK3-positive rate ≥50% showed a stronger correlation with them (both p = 0.001), which was validated by multivariate Cox regression analyses (both p < 0.05). <b>Conclusion:</b> Tumor PLK3-positive rate ≥50% relates to inc","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-06-26T03:06:26.64Z","creation":"2025-06-26T03:06:26.64Z"},"accession":"S-EPMC11216246","cross_references":{"pubmed":["38629862"],"doi":["10.2217/bmm-2023-0591"]}}